Market research
YP2A.F BioLineRx Ltd
F EUR Healthcare
Latest close
As of 01 May 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 452K
- P/E ratio
- Not available
- Analyst target
- 14.5
- Dividend yield
- Not available
- Beta
- 0.87
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 452K
- P/E ratio
- Not available
- Analyst target
- 14.5
- Dividend yield
- Not available
- Beta
- 0.87
About
About BioLineRx Ltd
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Research context
BioLineRx Ltd appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the YP2A.F discussion.
5 years, 6 months ago
BioLineRx Ltd is currently in a long term uptrend where the price is trading 14.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
BioLineRx Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 21.5% to $-12M since the same quarter in the previous year.
Finally, its free cash flow grew by 0.3% to $-5M since the same quarter in the previous year.
Based on the above factors, BioLineRx Ltd gets an overall score of 3/5.